Can my patient get the melanoma mRNA vaccine now?

No. Intismeran (V940/mRNA-4157) is investigational and available only through the clinical trial. It is not registered by the TGA, not on the PBS, and not accessible outside a research setting. Regulatory submission has not yet occurred; approval, if granted, would still be several years away. For patients with high-risk resected melanoma, the accessible standard today is adjuvant pembrolizumab, and that should be the treatment discussion your oncology team is having.

How is this different from a preventive cancer vaccine?

This is a therapeutic vaccine, not a preventive one. It does not work before cancer develops. Instead, each vaccine is manufactured from the sequencing of the patient's own resected tumour — identifying neoantigens, the abnormal proteins that mark cancer cells. The vaccine trains the immune system to recognise and attack cells carrying those neoantigens. Combined with pembrolizumab, which blocks the checkpoint signals that otherwise stop immune cells attacking cancer, the two drugs work through complementary mechanisms. The result is tumour-specific immune targeting — different in design and purpose from HPV or hepatitis B vaccines.

Personalised mRNA melanoma vaccine cuts recurrence risk by 42%

The results of INTerpath-001 landed at ESMO Congress 2026 this week: a personalised mRNA cancer vaccine, combined with pembrolizumab, reduced the risk of melanoma recurrence or death by 42% in patients with completely resected high-risk disease. The trial was led by Professor Georgina Long of Melanoma Institute Australia, with six Australian centres among the 157 sites internationally.

If you have had melanoma removed and you are waiting to see whether it comes back, a 42% reduction in that risk is not an abstraction. It is the difference between most of the data points and fewer of them. The complication is one that will take several more years to close.

What the trial found

INTerpath-001 randomised 1,137 patients with stage IIB to IV melanoma to pembrolizumab plus intismeran or pembrolizumab alone. All participants had completely resected disease at high risk of recurrence and no prior systemic treatment. The primary endpoint was recurrence-free survival.

The hazard ratio for the combination arm was 0.58 — a 42% relative reduction in the risk of recurrence or death. Among patients who remained recurrence-free beyond six months, the result was sharper still: a hazard ratio of 0.42, meaning a 58% relative reduction.

Safety was a notable finding alongside efficacy. Adding intismeran to pembrolizumab did not increase pembrolizumab-related adverse events. The vaccine’s side effects — injection-site pain, headache, chills — were mostly transient and low-grade. Overall survival data are not yet available; the primary endpoint is solid but the question of whether the recurrence benefit translates to longer life will take more follow-up time.

How it works

Intismeran is a therapeutic vaccine, not a preventive one. It does not work the way a flu shot or an HPV vaccine works.

The patient’s resected tumour is sequenced to identify neoantigens: the abnormal proteins that distinguish cancer cells from healthy tissue and mark them as foreign to the immune system. An mRNA vaccine encoding the selected neoantigens is then manufactured specifically for that patient. Pembrolizumab, an anti-PD-1 checkpoint inhibitor, blocks the inhibitory signals that otherwise prevent immune cells from attacking cancer. The two drugs work through complementary mechanisms — one primes the target, the other removes the brake.

The result is a treatment designed around one person’s cancer. Intismeran is being developed jointly by Moderna and MSD, which manufactures pembrolizumab.

The Australian context

Melanoma Institute Australia reports that Australia has one of the world’s highest melanoma rates — roughly one new diagnosis every 30 minutes and one death every six hours. The trial’s leadership and six of its sites being Australian is not incidental. Australia carries a disproportionate share of the global melanoma burden, and the research infrastructure here reflects decades of investment in catching up with that reality.

This result is described by the trial team as proof of concept for individualised neoantigen therapy — meaning it demonstrates the mechanism works at sufficient scale to be convincing. If individualised mRNA vaccines can reliably amplify anti-tumour immunity in melanoma, the platform hypothesis extends to other solid tumours. This is a signal about a class of treatment, not just one disease.

Both-and: real result, long access timeline

The both-and here sits between what has been proven and what that proof can do right now.

The result is solid. A phase 3 randomised trial of 1,137 patients, with a hazard ratio of 0.58 on the primary endpoint, is not a preliminary signal. It is the kind of data that supports regulatory submission. The team presented at ESMO with results expected in the New England Journal of Medicine — the highest-profile venue in the field.

The complication is access and timeline. Clinical trial completion, full follow-up data, regulatory submission, TGA assessment, approval, and then funded access in Australia are a sequence that routinely takes the better part of a decade. The treatment is investigational. It is not accessible outside trials now, and it is not clear when it will be.

Patients with high-risk resected melanoma in Australia currently have adjuvant pembrolizumab as the evidence-based standard, and that remains the recommendation today. The INTerpath-001 result does not change what a GP or oncologist can offer this week. It tells us where the field is heading.

2 cents: what to say when patients ask

For GPs: patients will ask about this result. It is worth knowing the trial name, the hazard ratio, and the timeline. The honest answer is: real result, real promise, not accessible yet. Standard adjuvant pembrolizumab is the treatment to discuss with an oncologist.

For patients with high-risk resected melanoma who want to understand the trial, centres like Melanoma Institute Australia or Peter MacCallum Cancer Centre are the right places to ask about research access or upcoming follow-up trials.

For everyone else: the distance between a landmark ESMO result and PBS-funded access is where public health advocacy matters — expedited regulatory pathways and early access programs are the mechanisms that could close that gap faster.

Verdict: yes — a 42% reduction in melanoma recurrence in a well-powered phase 3 trial is a result worth knowing about. The treatment is investigational, but the result is real and the platform has implications beyond melanoma.